GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) is listed on the NSE in the Pharmaceuticals sector, Pharmaceuticals & Biotechnology industry. Market capitalisation: 45206.00 Cr. Figures below are as reported and are shown with their source and date.
GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company is headquartered in Mumbai, Maharashtra and currently employs 3,680 full-time employees. The firm is engaged in the business of manufacturing, distributing, and trading in pharmaceuticals. The company manufactures medicinal substances used in the manufacture of pharmaceuticals, such as antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts, and esters; glycosides and vegetable alkaloids, and chemically pure sugar. The company offers a range of prescription medicines, vaccines, and consumer healthcare products. Its medicine portfolio includes Adartrel, Bactroban, Combodart, and Duodart. Its vaccines portfolio includes Ambirix, Cervarix, Fendrix, and Havrix. The Company’s products include Betamethasone, Potassium Clavulanate with Amoxycillin and Pneumococcal Polysaccharide and Conjugate Vaccine. Its oral health products include Sensodyne, parodontax and Polident. Its manufacturing unit is located at Nashik.
Source: finedge · as of 2026-09-29
Last close (₹): 2,433.7
Source: quantro_screener_metrics_job · as of 2026-10-22
Source: quantro_screener_metrics_job · as of 2026-10-23
| Year ended | Revenue (₹ Cr) | PAT (₹ Cr) | EPS (₹) |
|---|---|---|---|
| Mar 2026 | 3,821.67 | 1,035.98 | 61.15 |
| Mar 2025 | 3,749.21 | 927.58 | 54.75 |
| Mar 2024 | 3,453.71 | 589.96 | 34.83 |
| Mar 2023 | 3,251.72 | 610.69 | 36.05 |
| Mar 2022 | 3,278.03 | 1,694.72 | 100.04 |
Source: finedge · as of 2026-07-21
Source: finedge · as of 2026-03-31
Source: quantro_company_profiles · as of 2026-10-23
Figures computed 2026-10-23.